When Novo Nordisk's core Indian patent for semaglutide expired on March 20, 2026, the pharmaceutical industry witnessed one of the fastest generic drug launches in recent memory. Within 48 hours, more than 15 generic versions flooded the Indian market from manufacturers including Sun Pharma, Dr. Reddy's, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Glenmark.
The ripple effects have been immediate. Synthetic semaglutide API prices have plummeted from approximately $900 per gram three years ago to $90-$160 per gram today. Recombinant variants have fallen to nearly $50 per gram. Industry analysts project an additional 20-30% decline as manufacturing capacity expands.
Generic semaglutide is now available at approximately Rs 1,250 per month in India - up to 90% less than branded Ozempic. Novo Nordisk responded by cutting Ozempic's India price by 48%. Zydus Lifesciences is launching a reusable pen delivery system under brand names Semaglyn, Mashema, and Altreme.
A preprint analysis estimates generic injectable semaglutide could be produced for $28-$140 per person-year, accessible across 160 countries covering 69% of the global type 2 diabetes burden and 84% of clinical obesity cases.
China's semaglutide patent protection is also lapsing in 2026. The International Diabetes Federation estimates nearly 148 million adults in China live with diabetes - the world's largest single-country diabetes market.
For API suppliers, the expanding customer base presents volume-driven growth opportunities. For CDMOs, the surge in generic production drives demand for scalable manufacturing capacity. Companies with expertise in peptide synthesis and multi-market regulatory filings are well positioned.
The next 12-18 months represent a critical window for pharmaceutical companies in the API, intermediates, and contract manufacturing space.
